MIAMI

迈阿密

,

，

March 26, 2026

2026年3月26日

/PRNewswire/ -- Miami based eMed today announced it has raised $200 million in funding at a $2 billion plus valuation.

/PRNewswire/ -- 总部位于迈阿密的eMed今天宣布，已以超过20亿美元的估值筹集了2亿美元的资金。

The $200 million plus round brings together lead investor AON Consulting, Inc., with prominent investors such as NFL legend and eMed Founding Chief Wellness Officer

这笔超过2亿美元的融资回合汇集了主要投资者AON咨询公司和诸如NFL传奇人物、eMed创始首席健康官等知名投资者。

Tom Brady

汤姆·布雷迪

, alongside

，与...一起

Jeff Aronin

杰夫·阿罗尼斯

, Founder, Chairman and CEO of Paragon Biosciences;

，Paragon Biosciences 创始人、董事长兼首席执行官；

Ara Cohen

阿拉·科恩

, Co-Founder and Co-Managing Member of Knighthead Capital Management;

Knighthead Capital Management的联合创始人兼联合管理成员；

Antonio Gracias

安东尼奥·格雷西亚斯

, Founder and CEO of Valor Equity Partners;

，Valor Equity Partners 的创始人兼首席执行官；

Joe Lonsdale

乔·朗斯代尔

, Founder and Managing Partner at 8VC and Co-Founder of Palantir;

8VC创始人兼管理合伙人，Palantir联合创始人；

R.J. Melman

R.J. 梅尔曼

, CEO, Lettuce Entertain You Restaurants;

，首席执行官，生菜娱乐你餐厅；

Tom Ricketts

汤姆·里基茨

, Chairman of the Chicago Cubs; and former X CEO and current eMed CEO

芝加哥小熊队董事长；前X首席执行官兼现任eMed首席执行官

Linda Yaccarino

琳达·雅卡里诺

.

。

'I believe eMed's empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula. That conviction is why I've chosen to invest both my time as Founding Chief Wellness Officer and my capital in the company,' said Tom Brady.

“我相信eMed的富有同理心的代理人工智能平台，结合其员工和合作伙伴的实力，代表了一个真正的成功公式。这种信念就是我选择作为创始首席健康官投入时间并投资该公司的原因，”汤姆·布雷迪表示。

The closing of the Series A further confirms eMed's momentum and establishes the company as the definitive employer platform for population health at scale. Proceeds from the financing will be used to further advance eMed's agentic AI platform, while also strengthening the balance sheet to support and fund a new capitated model designed to help employers bend the healthcare cost curve.

A轮融资的完成进一步证实了eMed的发展势头，并确立了该公司作为大规模人口健康管理的权威雇主平台地位。融资所得将用于进一步推进eMed的代理人工智能平台，同时增强资产负债表，以支持和资助一种旨在帮助雇主降低医疗成本曲线的新型按人头付费模式。

.

。

GLP-1

GLP-1

medications are the most requested workplace benefit, yet only one in five companies provide the benefit. eMed is changing that.

药品是最受职场人士欢迎的福利，但只有五分之一的公司提供这种福利。eMed 正在改变这一现状。

eMed is the gold standard in clinically managed

eMed 是临床管理方面的黄金标准

GLP-1

GLP-1

programs for employers. At the core is a fundamental reality: GLP-1s are among the most significant therapeutic advances of our time, but their impact is only realized when patients stay on treatment. By achieving more than 90% member adherence, more than double the industry norm, eMed's program delivers what others cannot: employees who stay the course and see real results, including an average weight loss of 21 pounds, with 99% seeing improvement in at least one key biomarker within six months..

雇主项目。其核心是一个基本的事实：GLP-1 是我们这个时代最重大的治疗进展之一，但它们的效果只有在患者坚持治疗时才能显现。通过实现超过 90% 的成员依从性，这一数字是行业平均水平的两倍多，eMed 的项目实现了其他项目无法做到的目标：员工坚持治疗并看到切实的成果，包括平均减重 21 磅，并且 99% 的人在六个月内至少有一项关键生物标志物得到改善。

SOURCE eMed Population Health

来源：eMed人口健康

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示